Publications by authors named "Analia Azaro"

Claim this Profile
A
A Phase 1/2A trial of idroxioleic acid: first-in-class sphingolipid regulator and glioma cell autophagy inducer with antitumor activity in refractory glioma.
Juanita Lopez, Julia Lai-Kwon, Rhoda Molife, Liam Welsh, Nina Tunariu, Analía Azaro

Br J Cancer· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors.
Ignacio Melero, Tamara Tanos, Mariana Bustamante, Miguel F Sanmamed, Emiliano Calvo, Analia Azaro

Sci Transl Med· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER breast cancer.
Marta Palafox, Laia Monserrat, Meritxell Bellet, Guillermo Villacampa, Abel Gonzalez-Perez, Analía Azaro

Nat Commun· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER breast cancer.
Marta Palafox, Laia Monserrat, Meritxell Bellet, Guillermo Villacampa, Abel Gonzalez-Perez, Analía Azaro

Nat Commun· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer.
Mònica Sánchez-Guixé, Cinta Hierro, José Jiménez, Cristina Viaplana, Guillermo Villacampa, Analía Azaro

Clin Cancer Res· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations.
Sarina A Piha-Paul, Analía Azaro, Hendrik Tobias Arkenau, Do-Youn Oh, Matthew D Galsky

Invest New Drugs· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials.
Ignacio Matos, Guillermo Villacampa, Cinta Hierro, Juan Martin-Liberal, Roger Berché, Analia Azaro

Eur J Cancer· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors.
Analia Azaro, Christophe Massard, William D Tap, Philippe A Cassier, Jaime Merchan

Invest New Drugs· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 study of 2 high dose intensity schedules of the pan-Notch inhibitor crenigacestat (LY3039478) in combination with prednisone in patients with advanced or metastatic cancer.
Analía Azaro, Capucine Baldini, Jordi Rodon, Jean-Charles Soria, Eunice Yuen

Invest New Drugs· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors.
Richard D Baird, Constanza Linossi, Mark Middleton, Simon Lord, Adrian Harris, Analía Azaro

J Clin Oncol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours.
Petri Bono, Christophe Massard, Katriina J Peltola, Analía Azaro, Antoine Italiano

ESMO Open· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria.
Ignacio Matos, Juan Martin-Liberal, Alonso García-Ruiz, Cinta Hierro, Maria Ochoa de Olza, Analia Azaro

Clin Cancer Res· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohorts.
Yung-Jue Bang, Wu-Chou Su, Martin Schuler, Do-Hyun Nam, Wan Teck Lim, Analia Azaro

Cancer Sci· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma.
Martin van den Bent, Analia Azaro, Filip De Vos, Juan Sepulveda, W K Alfred Yung

J Neurooncol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
-
- and -Mutated Chemotherapy and Anti-EGFR-Refractory Colorectal Cancer: Should Clonality Guide Target Prioritization With Investigational Therapies?
Susana Aguilar, Cristina Santos, Giulia Martini, Guillem Argiles, Analia Azaro

JCO Precis Oncol· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication.
Meritxell Bellet, Faten Ahmad, Rafael Villanueva, Carolina Valdivia, Julián Palomino-Doza, Analía Azaro

Ther Adv Med Oncol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Notch pathway inhibition with LY3039478 in soft tissue sarcoma and gastrointestinal stromal tumours.
Olivier Mir, Analia Azaro, Jaime Merchan, Rashmi Chugh, Jonathan Trent

Eur J Cancer· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors.
Jordi Rodon, Giuseppe Curigliano, Jean-Pierre Delord, Wael Harb, Analia Azaro

Oncotarget· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatic safety analysis of trabectedin: results of a pharmacokinetic study with trabectedin in patients with hepatic impairment and experience from a phase 3 clinical trial.
Emiliano Calvo, Analia Azaro, Jordi Rodon, Luc Dirix, Manon Huizing

Invest New Drugs· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification.
Eric Angevin, Gianluca Spitaleri, Jordi Rodon, Katia Dotti, Nicolas Isambert, Analia Azaro

Eur J Cancer· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human phase I study of oral S49076, a unique MET/AXL/FGFR inhibitor, in advanced solid tumours.
Jordi Rodon, Sophie Postel-Vinay, Antoine Hollebecque, Paolo Nuciforo, Analia Azaro

Eur J Cancer· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unveiling changes in the landscape of patient populations in cancer early drug development.
Cinta Hierro, Analía Azaro, Guillem Argilés, Elena Elez, Patricia Gómez

Oncotarget· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I pharmacokinetic and safety study of cabazitaxel in adult cancer patients with normal and impaired renal function.
Analía Azaro, Jordi Rodón, Jean-Pascal Machiels, Sylvie Rottey, Silvia Damian

Cancer Chemother Pharmacol· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer.
Ivelina Gueorguieva, Ann Cleverly, Durisala Desaiah, Analia Azaro, Joan Seoane

Drugs Context· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy.
Meritxell Bellet, Kathryn P Gray, Prudence A Francis, István Láng, Eva Ciruelos, Analía Azaro

J Clin Oncol· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis